ArticleScientific reports2018
Investigating the potential use of an Antarctic variant of Janthinobacterium lividum for tackling antimicrobial resistance in a One Health approach.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 37 citations in OpenAlex.
- Distinct associations among human milk microbiota and minerals in relation to early infant growth: a longitudinal study.Journal of translational medicine · 2026Article
- Bioconversion of a Dairy By-Product (Microorganisms · 2025Article
- Probiotic, antimicrobial and anticancer properties of Lysinibacillus macroides, Kurthia huakuii, and Enterococcus faecium isolated from freshwater snail gut microbiota.BMC biotechnology · 2025Article
- A comprehensive review on violacein production by microbial fermentation.Biodesign research · 2025Review
- Chitin degradation by the aquatic pigment-producing bacteria of Janthinobacterium spp. from stream flows and springs of Shulgan River basin and Shulgan-Tash Cave, Southern Urals.Biodegradation · 2025Article
- Extracellular vesicles of Janthinobacterium lividum as violacein carriers in melanoma cell treatment.Applied microbiology and biotechnology · 2024Article
- Characterization of Antibiotic-Resistance AntarcticMicroorganisms · 2024Article
- Investigation of potential inhibitor properties of violacein against HIV-1 RT and CoV-2 Spike RBD:ACE-2.World journal of microbiology & biotechnology · 2022Article
- Isolation and Properties of the Bacterial StrainMicroorganisms · 2022Article
- Molecular signatures of Janthinobacterium lividum from Trinidad support high potential for crude oil metabolism.BMC microbiology · 2021Article
- Spatial Characterization of Microbial Communities on Multi-Species Leafy Greens Grown Simultaneously in the Vegetable Production Systems on the International Space Station.Life (Basel, Switzerland) · 2021Article
- Biotechnological Activities and Applications of Bacterial Pigments Violacein and Prodigiosin.Journal of biological engineering · 2021Review
- A Golden-Gate Based Cloning Toolkit to Build Violacein Pathway Libraries inACS synthetic biology · 2021Article
- Article
- Psychrotrophs of the genus3 Biotech · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this paper is to describe a new variant of Janthinobacterium lividum - ROICE173, isolated from Antarctic snow, and to investigate the antimicrobial effect of the crude bacterial extract against 200 multi-drug resistant (MDR) bacteria of both clinical and environmental origin, displaying various antibiotic resistance patterns. ROICE173 is extremotolerant, grows at high pH (5.5-9.5), in high salinity (3%) and in the presence of different xenobiotic compounds and various antibiotics. The best violacein yield (4.59 ± 0.78 mg·g
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.